BTK and B-cell chronic lymphocytic leukemia: As the combinations of ibrutinib with immunochemotherapy or venetoclax have resulted in high rates of MRD negativity in patients with untreated CLL [20, 21], it would be interesting to see whether combining non-covalent BTK inhibitors with immunochemotherapy or venetoclax produces similar effects in patients with CLL.